Company: MBIO
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001104659-25-018303
Chunk: 4

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-27
Form: 424B3
Chunk 4
---
eto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit 
 No.     
 2.1     
 10.1    |     | Description                                                                                                                  
 Bill of                                                                                                                      
 Sale and Surrender Agreement, dated January 31, 2025, by and between Mustang Bio, Inc. and AbbVie Bioresearch Center Inc.    
 First                                                                                                                        
 Amendment to Lease Agreement, dated February 7, 2025, by and between Mustang Bio, Inc. and WCS - 377 Plantation Street, Inc. |
|:--------|:----|:-----------------------------------------------------------------------------------------------------------------------------|
| 99.1    |     | Press Release, dated February 27, 2025                                                                                       |
| 104     |     | Cover Page Interactive Data File (formatted                                                                                  
 as Inline XBRL)                                                                                                              |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of
the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

| Date: February 27, 2025 | Mustang Bio, Inc. 
 (Registrant)      |                                        |
|:------------------------|:------------------|:---------------------------------------|
|                         | By:               | /s/ Manuel Litchman, M.D.              |
|                         | Name:             | Manuel Litchman, M.D.                  |
|                         | Title:            | President, Chief Executive Officer and |
|                         |                   | Interim Chief Financial Officer        |

Exhibit 2.1

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED
FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
[***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

<div align='center'>BILL OF SALE AND SURRENDER AGREEMENT</div>

This BILL OF SALE AND SURRENDER AGREEMENT(this “Bill of Sale Agreement”) is made and entered into as of the 31st day of January 2025 (being
the Agreement Date, as defined in Paragraph 1 below), by and between Mustang Bio, Inc.,a Delaware corporation (“Seller”)
and AbbVie Bioresearch Center Inc.,a Delaware corporation (“Buyer”).

<div align='center'>RECITALS</div>